The gene therapy that cures “bubble boy disease” isn’t worth it to Glaxo – MIT Technology Review
MIT Technology Review |
The gene therapy that cures “bubble boy disease” isn't worth it to Glaxo
MIT Technology Review An analyst at Goldman Sachs asked a troubling question this week about gene therapy. “Is curing patients a sustainable business model?” In social media, reactions were quick and sharp. “Cold and immoral.” “Capitalism at its finest.” But the Goldman … Lonza makes gene therapy ambitions clear with Texas plant Recon: GSK Sells Gene Therapy Assets |
